Evidence map›Paper›PMID 30252592›Full record

ArticlemAbs

Comprehensive manipulation of glycosylation profiles across development scales.

Sven Loebrich, Elisa Clark, Kristina Ladd, Stefani Takahashi, Anna Brousseau, Seth Kitchener, Robert Herbst, Thomas Ryll

Abstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sven Loebricha Cell Line and Upstream Process Development , Waltham , USA.ORCID 0000-0003-3530-5085
Elisa Clarka Cell Line and Upstream Process Development , Waltham , USA.ORCID 0000-0003-4267-7215
Kristina Ladda Cell Line and Upstream Process Development , Waltham , USA.
Stefani Takahashib Technical Operations , ImmunoGen, Waltham , USA.
Anna Brousseaub Technical Operations , ImmunoGen, Waltham , USA.
Seth Kitchenera Cell Line and Upstream Process Development , Waltham , USA.
Robert Herbstb Technical Operations , ImmunoGen, Waltham , USA.
Thomas Ryllb Technical Operations , ImmunoGen, Waltham , USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The extent and pattern of glycosylation on therapeutic antibodies can influence their circulatory half-life, engagement of effector functions, and immunogenicity, with direct consequences to efficacy and patient safety. Hence, controlling glycosylation patterns is central to any drug development program, yet poses a formidable challenge to the bio-manufacturing industry. Process changes, which can affect glycosylation patterns, range from manufacturing at different scales or sites, to switching production process mode, all the way to using alternative host cell lines. In the emerging space of biosimilars development, often times all of these aspects apply. Gaining a deep understanding of the direction and extent to which glycosylation quality attributes can be modulated is key for efficient fine-tuning of glycan profiles in a stage appropriate manner, but establishment of such platform knowledge is time consuming and resource intensive. Here we report an inexpensive and highly adaptable screening system for comprehensive modulation of glycans on antibodies expressed in CHO cells. We characterize 10 media additives in univariable studies and in combination, using a design of experiments approach to map the design space for tuning glycosylation profile attributes. We introduce a robust workflow that does not require automation, yet enables rapid process optimization. We demonstrate scalability across deep wells, shake flasks, AMBR-15 cell culture system, and 2 L single-use bioreactors. Further, we show that it is broadly applicable to different molecules and host cell lineages. This universal approach permits fine-tuned modulation of glycan product quality, reduces development costs, and enables agile implementation of process changes throughout the product lifecycle.

Indexed as

AnimalsAntibodies, MonoclonalCHO CellsCricetinaeCricetulusDrug DevelopmentGlycosylationHumansPolysaccharidesAntibodies, MonoclonalPolysaccharidesADCDoEfeed additivesglycosylationmedia developmentmultivariate analysisproduct qualityscalability

Identifiers

PMID30252592
PMCPMC6380396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.